S&P 500   5,011.18 (+0.88%)
DOW   38,245.95 (+0.68%)
QQQ   419.79 (+1.24%)
AAPL   166.72 (+1.04%)
MSFT   401.50 (+0.60%)
META   484.91 (+0.80%)
GOOGL   157.25 (+2.05%)
AMZN   177.42 (+1.60%)
TSLA   142.16 (-3.33%)
NVDA   794.78 (+4.30%)
AMD   148.65 (+1.37%)
NIO   4.02 (+5.79%)
BABA   70.87 (+2.61%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   109.67 (+2.72%)
GE   150.63 (+1.74%)
CGC   7.81 (-1.51%)
DIS   112.40 (-0.19%)
AMC   3.42 (+8.23%)
PFE   26.36 (+1.38%)
PYPL   63.34 (+1.65%)
XOM   120.79 (+0.76%)
S&P 500   5,011.18 (+0.88%)
DOW   38,245.95 (+0.68%)
QQQ   419.79 (+1.24%)
AAPL   166.72 (+1.04%)
MSFT   401.50 (+0.60%)
META   484.91 (+0.80%)
GOOGL   157.25 (+2.05%)
AMZN   177.42 (+1.60%)
TSLA   142.16 (-3.33%)
NVDA   794.78 (+4.30%)
AMD   148.65 (+1.37%)
NIO   4.02 (+5.79%)
BABA   70.87 (+2.61%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   109.67 (+2.72%)
GE   150.63 (+1.74%)
CGC   7.81 (-1.51%)
DIS   112.40 (-0.19%)
AMC   3.42 (+8.23%)
PFE   26.36 (+1.38%)
PYPL   63.34 (+1.65%)
XOM   120.79 (+0.76%)
S&P 500   5,011.18 (+0.88%)
DOW   38,245.95 (+0.68%)
QQQ   419.79 (+1.24%)
AAPL   166.72 (+1.04%)
MSFT   401.50 (+0.60%)
META   484.91 (+0.80%)
GOOGL   157.25 (+2.05%)
AMZN   177.42 (+1.60%)
TSLA   142.16 (-3.33%)
NVDA   794.78 (+4.30%)
AMD   148.65 (+1.37%)
NIO   4.02 (+5.79%)
BABA   70.87 (+2.61%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   109.67 (+2.72%)
GE   150.63 (+1.74%)
CGC   7.81 (-1.51%)
DIS   112.40 (-0.19%)
AMC   3.42 (+8.23%)
PFE   26.36 (+1.38%)
PYPL   63.34 (+1.65%)
XOM   120.79 (+0.76%)
S&P 500   5,011.18 (+0.88%)
DOW   38,245.95 (+0.68%)
QQQ   419.79 (+1.24%)
AAPL   166.72 (+1.04%)
MSFT   401.50 (+0.60%)
META   484.91 (+0.80%)
GOOGL   157.25 (+2.05%)
AMZN   177.42 (+1.60%)
TSLA   142.16 (-3.33%)
NVDA   794.78 (+4.30%)
AMD   148.65 (+1.37%)
NIO   4.02 (+5.79%)
BABA   70.87 (+2.61%)
T   16.31 (-1.21%)
F   12.83 (+5.68%)
MU   109.67 (+2.72%)
GE   150.63 (+1.74%)
CGC   7.81 (-1.51%)
DIS   112.40 (-0.19%)
AMC   3.42 (+8.23%)
PFE   26.36 (+1.38%)
PYPL   63.34 (+1.65%)
XOM   120.79 (+0.76%)

Sanofi (SNY) Competitors

$46.94
+0.64 (+1.38%)
(As of 03:27 PM ET)

SNY vs. VRTX, REGN, BMY, PFE, GSK, ZTS, ABT, TAK, NVS, and BIIB

Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), Pfizer (PFE), GSK (GSK), Zoetis (ZTS), Abbott Laboratories (ABT), Takeda Pharmaceutical (TAK), Novartis (NVS), and Biogen (BIIB). These companies are all part of the "medical" sector.

Sanofi vs.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Vertex Pharmaceuticals received 1514 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.

CompanyUnderperformOutperform
Vertex PharmaceuticalsOutperform Votes
1547
75.65%
Underperform Votes
498
24.35%
SanofiOutperform Votes
33
53.23%
Underperform Votes
29
46.77%

Vertex Pharmaceuticals currently has a consensus price target of $429.45, suggesting a potential upside of 7.72%. Sanofi has a consensus price target of $55.00, suggesting a potential upside of 17.40%. Given Vertex Pharmaceuticals' higher possible upside, analysts plainly believe Sanofi is more favorable than Vertex Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals
3 Sell rating(s)
6 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.48
Sanofi
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Vertex Pharmaceuticals has a net margin of 36.68% compared to Vertex Pharmaceuticals' net margin of 12.56%. Vertex Pharmaceuticals' return on equity of 27.47% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals36.68% 21.91% 16.73%
Sanofi 12.56%27.47%16.07%

Vertex Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.

In the previous week, Vertex Pharmaceuticals had 17 more articles in the media than Sanofi. MarketBeat recorded 38 mentions for Vertex Pharmaceuticals and 21 mentions for Sanofi. Sanofi's average media sentiment score of 0.65 beat Vertex Pharmaceuticals' score of 0.36 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vertex Pharmaceuticals
18 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Sanofi
8 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 10.0% of Sanofi shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sanofi has higher revenue and earnings than Vertex Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$9.87B10.54$3.62B$13.8928.98
Sanofi$46.44B2.56$5.84B$2.3619.91

Summary

Vertex Pharmaceuticals beats Sanofi on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNY vs. The Competition

MetricSanofiPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$118.84B$6.27B$4.64B$7.31B
Dividend Yield3.03%3.10%5.46%3.98%
P/E Ratio19.917.92181.0616.24
Price / Sales2.56302.982,596.1880.96
Price / Cash7.2419.0131.1927.20
Price / Book1.485.594.594.45
Net Income$5.84B$136.96M$99.84M$212.71M
7 Day Performance1.60%-0.53%108.82%-0.25%
1 Month Performance-2.27%-6.92%106.69%-1.31%
1 Year Performance-17.14%1.55%132.80%5.49%

Sanofi Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRTX
Vertex Pharmaceuticals
4.3509 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+19.1%$101.88B$9.87B28.385,400Analyst Downgrade
Analyst Revision
REGN
Regeneron Pharmaceuticals
3.6799 of 5 stars
$894.14
-0.5%
$970.57
+8.5%
+12.0%$98.14B$13.12B25.7313,450Analyst Downgrade
BMY
Bristol-Myers Squibb
4.5759 of 5 stars
$48.27
-0.5%
$61.12
+26.6%
-30.6%$97.83B$45.01B12.5134,100Upcoming Earnings
Analyst Revision
PFE
Pfizer
4.99 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-35.3%$145.47B$58.50B71.3688,000
GSK
GSK
2.9303 of 5 stars
$39.95
-1.4%
N/A+8.3%$82.78B$37.71B13.2770,200Options Volume
ZTS
Zoetis
4.8464 of 5 stars
$153.02
+2.2%
$221.75
+44.9%
-17.2%$69.99B$8.54B30.1814,100Gap Up
ABT
Abbott Laboratories
4.9959 of 5 stars
$109.20
+0.3%
$122.14
+11.9%
-3.9%$189.48B$40.11B33.50114,000Earnings Report
Analyst Report
Analyst Revision
TAK
Takeda Pharmaceutical
0.3161 of 5 stars
$13.24
+0.5%
$14.00
+5.7%
-21.4%$41.90B$4.17T20.0649,095News Coverage
NVS
Novartis
2.4656 of 5 stars
$93.19
-1.3%
$104.33
+12.0%
-5.9%$197.53B$45.44B12.9876,057Upcoming Earnings
BIIB
Biogen
4.9204 of 5 stars
$195.15
-0.8%
$298.96
+53.2%
-33.9%$28.37B$9.84B24.457,570Upcoming Earnings
Analyst Report
Analyst Revision

Related Companies and Tools

This page (NASDAQ:SNY) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners